Evidence map›Paper›PMID 32656347›Full record

ArticleCannabis and cannabinoid research2020

Cannabidiol-Enriched Extract Reduced the Cognitive Impairment but Not the Epileptic Seizures in a Lafora Disease Animal Model.

Ester Aso, Pol Andrés-Benito, Jordi Grau-Escolano, Laura Caltana, Alicia Brusco, Pascual Sanz, Isidre Ferrer

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cannabis and cannabinoid research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Virtual Screening ofInternational journal of molecular sciences · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 2 countries.

Ester AsoUnitat de Farmacologia, Departament de Patologia i Terapèutica Experimental, Facultat de Medicina i Ciències de la Salut, IDIBELL, Universitat de Barcelona, L'Hospitalet de Llobregat, Spain.
Pol Andrés-BenitoInstitut de Neurociències, Universitat de Barcelona, Barcelona, Spain.
Jordi Grau-EscolanoUnitat de Farmacologia, Departament de Patologia i Terapèutica Experimental, Facultat de Medicina i Ciències de la Salut, IDIBELL, Universitat de Barcelona, L'Hospitalet de Llobregat, Spain.
Laura CaltanaInstituto de Biología Celular y Neurociencia Prof. E. de Robertis (IBCN, UBA-CONICET), Facultad de Medicina, Universidad de Buenos Aires, Buenos Aires, Argentina.
Alicia BruscoInstituto de Biología Celular y Neurociencia Prof. E. de Robertis (IBCN, UBA-CONICET), Facultad de Medicina, Universidad de Buenos Aires, Buenos Aires, Argentina.
Pascual SanzInstituto de Biomedicina de Valencia, Consejo Superior de Investigaciones Científicas (IBV-CSIC), Valencia, Spain.
Isidre FerrerInstitut de Neurociències, Universitat de Barcelona, Barcelona, Spain.
Biomedical Research Networking Center on Neurodegenerative Diseases · ESInstitut d'Investigació Biomédica de Bellvitge · ESUniversidad de Buenos Aires · ARConsejo Superior de Investigaciones Científicas · ES

Funding

Suppressing glycogen storage with small molecule inhibitors as a therapeutic approach to Lafora DiseaseP01NS097197 · NINDS · UNIVERSITY OF KENTUCKY · PI GAO, TIANYAN · 2016 to 2021
$9.0M
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

cannabidiolcannabinoidsepilepsyLafora diseaseneurodegeneration

Identifiers

PMID32656347
PMCPMC7347043
OpenAlexW2953878335

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.